PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

BaseCure collaborates with Aptamer Group to boost gene therapies

Binders will establish cell types and delivery vehicles that may increase the uptake of the siRNA therapy.

Aptamer Group – a company that focuses on developing innovative novel binders across its Optimer-based platform – has revealed a new link-up with BaseCure Therapeutics. The partnership will primarily concentrate on emerging Optimer-targeted gene therapies.

It will also involve precisely targeting gene therapies – like small interfering ribonucleic acid (siRNA) therapeutics – to establish tissues and cells by incorporating the Optimer platform. Both companies are confident that the partnership will yield a wealth of new opportunities across the field of gene therapy.

Optimer binders are oligonucleotide affinity ligands that are essentially antibody alternatives. Crucially, they can also be combined with various payloads – from small molecule drugs to gene therapies.

Furthermore, in terms of the gene therapy market, siRNA therapies represent the most significant element of this rapidly growing area, with consistent potential emerging from the clinic. Indeed, so far, there have been US Food and Drug Administration approval of four siRNA treatments.

In spite of this success, however, targeting the drug to a specific organ or cell within the body, and allowing its gene-silencing function, is still a huge obstacle. Consequently, the new partnership aims to support the future development of more targeted gene therapies.

Dr Arron Tolley, chief executive officer at Aptamer, is optimistic about the collaboration: “We’re excited to work with BaseCure Therapeutics to develop Optimer delivery vehicles that improve the effectiveness of their siRNA therapies.”

“Targeted delivery remains a significant challenge to the therapeutic oligonucleotide market, so we are pleased to be able to offer solutions for this using our Optimer platform. I look forward to updating the market regarding progress in due course,” he added.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026